GB202300774D0 - A novel medicament for immune modulation and treating chronic or hyper inflammation - Google Patents

A novel medicament for immune modulation and treating chronic or hyper inflammation

Info

Publication number
GB202300774D0
GB202300774D0 GBGB2300774.3A GB202300774A GB202300774D0 GB 202300774 D0 GB202300774 D0 GB 202300774D0 GB 202300774 A GB202300774 A GB 202300774A GB 202300774 D0 GB202300774 D0 GB 202300774D0
Authority
GB
United Kingdom
Prior art keywords
treating chronic
immune modulation
novel medicament
hyper
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2300774.3A
Other versions
GB2612481A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elkazaz Mohamed Fadly Abd
Original Assignee
Elkazaz Mohamed Fadly Abd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elkazaz Mohamed Fadly Abd filed Critical Elkazaz Mohamed Fadly Abd
Publication of GB202300774D0 publication Critical patent/GB202300774D0/en
Publication of GB2612481A publication Critical patent/GB2612481A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB2300774.3A 2020-06-09 2021-06-07 A novel medicament for immune modulation and treating chronic or hyper inflammation Pending GB2612481A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EG2020060768 2020-06-09
PCT/EG2021/000016 WO2021249608A2 (en) 2020-06-09 2021-06-07 A novel medicament for immune modulation and treating chronic or hyper inflammation

Publications (2)

Publication Number Publication Date
GB202300774D0 true GB202300774D0 (en) 2023-03-08
GB2612481A GB2612481A (en) 2023-05-03

Family

ID=78845336

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2300774.3A Pending GB2612481A (en) 2020-06-09 2021-06-07 A novel medicament for immune modulation and treating chronic or hyper inflammation

Country Status (3)

Country Link
AU (1) AU2021286756A1 (en)
GB (1) GB2612481A (en)
WO (1) WO2021249608A2 (en)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69332641T2 (en) * 1992-08-31 2003-11-27 University Of Florida Research Foundation, Inc. ANABASEIN DERIVATIVES FOR TREATING DEGENERATIVE DISEASES OF THE NERVOUS SYSTEM
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
WO2005123075A2 (en) * 2004-06-08 2005-12-29 University Of Florida Research Foundation, Inc. Controlling angiogenesis with anabaseine analogs
US7662965B2 (en) * 2006-01-26 2010-02-16 Cornerstone Therapeutics, Inc. Anabaseine derivatives, pharmaceutical compositions and method of use thereof
US20130053355A1 (en) * 2011-08-29 2013-02-28 Rock Creek Pharmaceuticals, Inc. Products for anti-inflammation support
US10667515B2 (en) * 2016-11-20 2020-06-02 Iowa State University Research Foundation, Inc. (S)-5-ethynyl-anabasine, derivatives thereof, and related compositions and methods of making and using
AU2019256805B2 (en) * 2018-04-16 2022-03-03 Poviva Corp. Compositions infused with nicotine compounds and methods of use thereof

Also Published As

Publication number Publication date
GB2612481A (en) 2023-05-03
WO2021249608A3 (en) 2022-02-03
AU2021286756A1 (en) 2023-03-23
WO2021249608A2 (en) 2021-12-16
WO2021249608A4 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
MX2018004947A (en) Methods for treating angelman syndrome and related disorders.
EP4076225A4 (en) Devices and methods for treating vascular occlusion
IL271212A (en) Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
IL292040A (en) Devices and methods for modulating immune system activity in a cancer patient and treating cancer
IL283598A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
IL290123A (en) Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
PL3862000T3 (en) Medicine for treating chronic cough
IL275940A (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
IL272546A (en) Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody
EP4072439A4 (en) Injection and infusion site treatment devices and methods
IL284225A (en) Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
IL279789A (en) Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
EP3897725A4 (en) Combination of radioimmunotherapy and immune checkpoint therapy in the treatment of cancer
GB202300774D0 (en) A novel medicament for immune modulation and treating chronic or hyper inflammation
EP3752247A4 (en) Immune dose computation for treatment plan optimization in radiotherapy
GB2590793B (en) Cannabidiol-C1 for use as a medicament and in the treatment of epilepsy
EP4041304A4 (en) Treatment of cancer using a combination comprising multi-tyrosine kinase inhibitor and immune checkpoint inhibitor
EP4003375A4 (en) Depletion regimes for engineered t-cell or nk-cell therapy
IL288178A (en) Gmci and ddri combination therapy for treating cancer
EP3956358A4 (en) Alpha4beta7 inhibitor and il-23 inhibitor combination therapy
EP3976134A4 (en) Devices and methods for administering a therapeutic preparation
EP3801550A4 (en) Maintenance therapy of a parp inhibitor in treating gastric cancer
GB202205294D0 (en) Infusion devices and components thereof
GB202207515D0 (en) Infusion devices and associated methods
GB202205305D0 (en) Infusion devices and associated methods